Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,082.99
(
-0.37%
)
US TECH 100
25,836.80
(
-0.13%
)
Dow Jones
49,246.99
(
-0.41%
)
Brent Oil
96.61
(
6.54%
)
Bitcoin
74,995.47
(
-1.18%
)
News Focus
News Focus
Post# of 257432
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 224629

Friday, 09/20/2019 10:58:25 AM

Friday, September 20, 2019 10:58:25 AM

Post# of 257432
FDA approves NVO’s Rybelsus (semaglutide)—the first oral GLP-1 for T2D:

https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes

Rybelsus is also being tested in NASH, pursuant to a collaboration with GILD (#msg-148185301).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today